1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581–92.
2. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002.CA Cancer J Clin 2005; 55 (2): 74–108.
3. Cardoso F, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): iv15–iv18.
4. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–52.
5. Onitilo A, Engel JM, Greenlee RT et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009; 7: 4–13.
6. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene xpression profiles from a population-based study. Proc Natl Acad Sc i USA 2003; 100: 10393–8.
7. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008; 19: 16–27.
8. Gullick WJ et al. c-ErbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434–8.
9. Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family recep-tor tyrosine kinases. Breast Cancer Res 2000; 2: 176–83.
10. Martin M. Molecular biology of breast cancer. Clin Transl Oncol 2006; 8: 7–14.
11. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82.
12. Witton CJ, Reeves JR, Going JJ et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200: 290–7.
13. Pestrin M et al. Proc. Eur Breast Cancer Conf 2008.
14. Piccart-Gebhart et al. N Engl J Med 2005; 353: 1659–72.
15. Brenton et al. J Clin Oncol 2005; 23: 7350–60.
16. Johnston S. Clin Cancer Res 2005; 11: 889S–99S.
17. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24 (2): 85–95.
18. Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and romotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10 (12): 2435–46.
19. Shin I, Miller T, Arteaga CL. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin Cancer Res 2006; 12 (3 Pt 2): 1008s–12.
20. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 2008; 5: 531–42.
21. Paik S. Molecular profiling of breast cancer. Curr Opin Obstet Gynecol 2006; 18: 59–63.
22. Orman JS, Perry CM. Trastuzumab: in HER2 and hormone receptor co-positive metastatic breast cancer. Drugs 2007; 67 (18): 2781–9.
23. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62 (1): 209–43.
24. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27 (33): 5529–37.
25. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533–43.
26. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630–9.
27. Rusnak DW, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 8.
28. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64 (18): 6652–9.
29. TYKERB (lapatinib tablets): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2009.
30. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21 (41): 6255–63.
31. Chu I, Blackwell K, Chen S et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogendependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005; 65 (1): 18–25.
32. Johnston S, Pippen JrJ, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27 (33): 5538–46.
33. Schwarzberg LS, Franco SX, Florance A et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010; 15 (2): 122–9.
34. Sherif BN, Sherrill B, Amonkar M et al. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+ metastatic breast cancer: a quality-of-life analysis. J Clin Oncol 2009; 27 (Suppl. 15): 50s.
35. Sherrill B, Amonkar M, Sherif B et al. A QTWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR+) metastatic breast cancer (MBC). Eur J Cancer Suppl 2009; 7 (2): 275.
36. Wilcken N, Hornbuckle J, Ghersi D Chemotherapy Alone Versus Endocrine Therapy Alone for Metastatic Breast Cancer Cochrane Database Syst Rev. 2003; (2): CD002747.

И.В.Поддубная1, О.Н.Матвеева2

1 РОНЦ им. Н.Н.Блохина РАМН, Москва;
2 Медицинский отдел GSK